Cartesian Therapeutics, Inc. (NASDAQ:RNAC) announced a strategic partnership with WestGene Biopharma to develop novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies aimed at treating autoimmune diseases. This collaboration is expected to enhance Cartesian's clinical prospects significantly. Under the agreement, WestGene will receive an upfront payment along with potential development and commercial milestone payments. The partnership aims to initiate clinical trials in the second half of 2026, targeting patients with myasthenia gravis, with clinical data anticipated in the first half of 2027. Currently, Cartesian's stock is priced at $6.50, reflecting a short-term bearish trend as it sits 7.3% below its 20-day simple moving average. Despite this, analysts maintain a Buy rating for the stock, with an average price target of $29.75, indicating potential for significant upside as developments unfold. Investors are advised to closely monitor the company's progress in its strategic partnerships and upcoming clinical trials.